Redeye retains its positive view of Sdiptech following a Q2 report that met our expectations. The company continues to perform strongly with organic growth figures well above peers and sustained margins. We believe continued stable results will drive the stock upwards from here and nudge up our base case fair value per share.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/